Scientists from the Centers for Disease Control and Prevention (CDC) and the New York State Department of Health reported today that three cases of pan-resistant Candida auris have been identified in New York.
The three patients were treated at separate hospitals in New York City, which has the most confirmed C auris cases in the country, at 427. Samples from the three patients were resistant to all three classes of commonly prescribed antifungal drugs—flucanazole, amphotericin B, and echinocandins. Subsequent investigations found no transmission of pan-resistant C auris to other patients or the environment.
C auris is a fungus that was first identified in Japan in 2009, and first appeared in the United States in 2016. It’s often resistant to more than one antifungal medication and causes severe invasive infections in hospitalized patients, with associated mortality rates of higher than 30%. Hospitals in more than 30 countries have reported multiple cases, with several reporting outbreaks.
Although the overall number of cases in the United States is small, public health officials have expressed concern about C auris because of the limited treatment options for infected patients, high mortality rates, and the ability of the pathogen to spread easily in healthcare settings.
Resistance emerged after treatment
Read more at CIDRAP…